ONE of the most frustrating features of primary biliary cirrhosis is pruritus, often so intense and unrelenting that the victim seriously contemplates suicide.1 Such patients suffer from chronic in ...

The ongoing, global phase 3 GLISTEN study (ClinicalTrials.gov Identifier: NCT04950127) enrolled 238 adult PBC patients with moderate to severe pruritus who were receiving stable doses of guideline ...

Pruritus-related sleep interference was also reduced with linerixibat, with a mean change of -2.77 versus -2.24 (P=0.024), and more patients in the linerixibat group had clinically meaningful itch ...

Medically reviewed by Jay N. Yepuri, MD Primary biliary cholangitis ... Tricor (fenofibrate): Taken alongside Urso, Tricor ...

Annie Lowrey talks about chronic itch and primary biliary cholangitis Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments.

Liver disease can cause itching, which can be bothersome. Here, learn about some possible reasons and some ways to manage it.

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC). News release. GSK. June 2, 2025.

Pruritus, or itching, is a common symptom of Primary Biliary Cholangitis (PBC). Learn more about its impact and the importance of raising awareness about this condition.

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for ...

Phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025. BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ...

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.